Predicting the Incidence and Prognosis of Bone Metastatic Breast Cancer: A SEER-Based Observational Study

Table 1

Incidence of bone metastasis in different breast cancer molecular subtypes.

Characteristics	Luminal A			Luminal B			HER2			TNBC			value
	(HR+/HER2-)			(HR+/HER2+)			(HR-/HER2+)			(HR-/HER2-)
	Bone	All	(%)	Bone	All	(%)	Bone	All	(%)	Bone	All	(%)
Total	1800	28931	6.2	422	4502	9.4	178	2244	7.9	447	7007	6.4	<0.001
Age (yrs)
<40	104	1229	8.5	34	410	8.3	15	178	8.4	32	653	4.9	0.035
40-59	687	11834	5.8	193	2184	8.8	83	1071	7.7	189	3253	5.8	<0.001
≥60	1009	15868	6.4	195	1908	10.2	80	995	8	226	3101	7.3	<0.001
T stage
≤1	215	16607	1.3	49	1930	2.5	20	789	2.5	45	2217	2	<0.001
2	583	8515	6.8	127	1622	7.8	38	811	4.7	121	2870	4.2	<0.001
3	336	2059	16.3	79	470	16.8	29	263	11	85	912	9.3	<0.001
4	666	1750	38.1	167	480	34.8	91	381	23.9	196	1008	19.4	<0.001
N stage
0	427	18074	2.4	94	2337	4	35	973	3.6	82	3512	2.3	<0.001
1	831	7329	11.3	203	1394	14.6	82	759	10.8	217	2084	10.4	0.001
2	254	2064	12.3	55	443	12.4	25	275	9.1	60	706	8.5	0.023
3	288	1464	19.7	70	328	21.3	36	237	15.2	88	705	12.5	<0.001
Other metastases
Brain(+)lung(-)liver(-)	60	83	72.3	14	26	53.8	8	16	50	13	49	26.5	<0.001
Brain(-)lung(+)liver(-)	316	479	66	47	105	44.8	20	75	26.7	68	254	26.8	<0.001
Brain(-)lung(-)liver(+)	206	344	59.9	94	156	60.3	37	92	40.2	77	170	45.3	<0.001
Brain(+)lung(+)liver(-)	30	43	69.8	12	16	75	4	13	30.8	15	40	37.5	0.002
Brain(+)lung(-)liver(+)	16	21	76.2	8	9	88.9	5	10	50	9	12	75	0.264
Brain(-)lung(+)liver(+)	142	190	74.7	69	98	70.4	40	62	64.5	54	68	50	<0.001
Brain(+)lung(+)liver(+)	31	37	83.8	14	18	77.8	14	17	82.4	20	24	83.3	0.958
Brain(-)lung(-)liver(-)	999	27734	3.6	164	4074	4	50	1959	2.6	191	6350	3	0.003

HR: hormone receptor; HER2: human epidermal growth factor receptor 2; TNBC: triple-negative breast cancer.